RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

RBC Capital analyst Luca Issi maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $95.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

According to TipRanks, Issi is a 2-star analyst with an average return of 0.1% and a 39.47% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, uniQure, and Ascendis Pharma.

In addition to RBC Capital, Ionis Pharmaceuticals also received a Buy from Leerink Partners’s Mani Foroohar in a report issued on December 15. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).

Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending October 28, the company reported a quarterly revenue of $156.72 million and a GAAP net loss of $128.61 million. In comparison, last year the company earned a revenue of $133.81 million and had a GAAP net loss of $140.48 million

Based on the recent corporate insider activity of 127 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year. Last month, Joan Herman, a Director at IONS sold 44,000.00 shares for a total of $3,173,720.00.